Ergami Endoscopy

Ergami Endoscopy

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $13.8M

Overview

Ergami Endoscopy is an early-stage private company targeting a significant unmet need in gastroenterology: the physical strain of manual colonoscope insertion and patient discomfort during procedures. The company's core innovation is a cost-effective robotic system designed to automate the insertion phase, which could democratize access to robotic assistance in endoscopy suites. If successful, Ergami's technology has the potential to increase colonoscopy throughput, improve patient experience, and reduce work-related injuries for endoscopists and nurses, addressing both clinical and economic pain points in a high-volume procedure.

Gastroenterology

Technology Platform

Low-cost robotic system designed to automate the insertion phase of a colonoscopy, aiming to provide precise control, reduce physical strain on operators, and improve patient comfort.

Funding History

2
Total raised:$13.8M
Series A$12M
Seed$1.8M

Opportunities

The massive and growing volume of colonoscopy procedures creates a substantial addressable market, particularly in cost-sensitive ambulatory surgery centers.
A successful low-cost robotic solution could democratize access to robotic assistance, improving productivity and reducing musculoskeletal injuries for clinicians, while enhancing patient comfort and potentially increasing screening compliance.

Risk Factors

Significant technical and clinical risk exists in developing a system that matches the tactile skill of an experienced endoscopist.
The company faces regulatory uncertainty and formidable competition from large, established medtech players.
Commercial adoption risk is high, as convincing gastroenterologists to change their technique requires demonstrating clear clinical and economic value.

Competitive Landscape

The competitive landscape includes large-cap medtech companies like Intuitive Surgical (with its Ion platform for bronchoscopy, showing interest in flexible robotics) and Medtronic, as well as other startups in the endoscopic robotics space. Ergami's key differentiator is its focused, low-cost approach targeting only colonoscope insertion, as opposed to more complex and expensive multi-procedure robotic systems.